SOPHiA GENETICS Logo (IMAGE)

SOPHiA GENETICS SA

SOPHiA GENETICS Logo

Caption

SOPHiA GENETICS, in collaboration with AstraZeneca, conducted a study that leveraged advanced AI-driven techniques to identify subgroups of stage IV non-small cell lung cancer (NSCLC) patients who could most benefit from the addition of tremelimumab to durvalumab and chemotherapy.

Credit

SOPHiA GENETICS

Usage Restrictions

None

License

Original content

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.